scholarly journals Gentamicin Population Pharmacokinetics in Pediatric Patients—A Prospective Study with Data Analysis Using the saemix Package in R

Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1596
Author(s):  
Paolo Paioni ◽  
Vera F. Jäggi ◽  
Romy Tilen ◽  
Michelle Seiler ◽  
Philipp Baumann ◽  
...  

The aminoglycoside gentamicin is used for the empirical treatment of pediatric infections. It has a narrow therapeutic window. In this prospective study at University Children’s Hospital Zurich, Switzerland, we aimed to characterize the pharmacokinetics of gentamicin in pediatric patients and predict plasma concentrations at typical recommended doses. We recruited 109 patients aged from 1 day to 14 years, receiving gentamicin (7.5 mg/kg at age ≥ 7 d or 5 mg/kg). Plasma levels were determined 30 min, 4 h and 24 h after the infusion was stopped and then transferred, together with patient data, to the secure BioMedIT node Leonhard Med. Population pharmacokinetic modeling was performed with the open-source R package saemix on the SwissPKcdw platform in Leonhard Med. Data followed a two-compartment model. Bodyweight, plasma creatinine and urea were identified as covariates for clearance, with bodyweight as a covariate for central and peripheral volumes of distribution. Simulations with 7.5 mg/kg revealed a 95% CI of 13.0–21.2 mg/L plasma concentration at 30 min after the stopping of a 30-min infusion. At 24 h, 95% of simulated plasma levels were < 1.8 mg/L. Our study revealed that the recommended dosing is appropriate. It showed that population pharmacokinetic modeling using R provides high flexibility in a secure environment.

2011 ◽  
Vol 51 (3) ◽  
pp. 333-345 ◽  
Author(s):  
W. Knebel ◽  
B. Tammara ◽  
C. Udata ◽  
G. Comer ◽  
M. R. Gastonguay ◽  
...  

Author(s):  
Christopher M. Rubino ◽  
Anthony P. Cammarata ◽  
Anne Smits ◽  
Sebastian Schröpf ◽  
Mark Polak ◽  
...  

Ceftobiprole is an advanced-generation cephalosporin for intravenous administration with activity against Gram-positive and Gram-negative organisms. A population pharmacokinetic (PK) model characterizing the disposition of ceftobiprole in plasma using data from patients in three pediatric studies was developed. Model-based simulations were subsequently performed to assist in dose optimization for the treatment of pediatric patients with hospital-acquired or community-acquired pneumonia. The population PK dataset comprised 518 ceftobiprole plasma concentrations from 107 patients aged 0 (birth) to 17 years. Ceftobiprole PK was well described by a three-compartment model with linear elimination. Ceftobiprole clearance was modeled as a function of glomerular filtration rate; other PK parameters were scaled to body weight. The final population PK model provided a robust and reliable description of the PK of ceftobiprole in the pediatric study population. Model-based simulations using the final model suggested that a ceftobiprole dose of 15 mg/kg infused over 2 hours and administered every 12 hours in neonates and infants <3 months or every 8 hours in older pediatric patients would result in a ceftobiprole exposure consistent with that in adults and good pharmacokinetic-pharmacodynamic target attainment. The dose should be reduced to 10 mg/kg every 12 hours in neonates and infants <3 months who weigh <4 kg to avoid high exposures. Extended intervals and reduced doses may be required for pediatric patients older than 3 months of age with renal impairment.


2015 ◽  
Vol 54 (8) ◽  
pp. 875-883 ◽  
Author(s):  
William Knebel ◽  
Mary Corcoran ◽  
James Ermer ◽  
Marc R. Gastonguay

2016 ◽  
Vol 33 (7) ◽  
pp. 1657-1670 ◽  
Author(s):  
Maiara Cássia Pigatto ◽  
Bibiana Verlindo de Araujo ◽  
Bruna Gaelzer Silva Torres ◽  
Stephan Schmidt ◽  
Paolo Magni ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document